Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients...
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
About this item
Full title
Author / Creator
Publisher
London: British Thoracic Society
Journal title
Language
English
Formats
Publication information
Publisher
London: British Thoracic Society
Subjects
More information
Scope and Contents
Contents
IntroductionThere is an unmet need for new treatments for idiopathic pulmonary fibrosis (IPF). The oral preferential phosphodiesterase 4B inhibitor, BI 1015550, prevented a decline in forced vital capacity (FVC) in a phase II study in patients with IPF. This study design describes the subsequent pivotal phase III study of BI 1015550 in patients wit...
Alternative Titles
Full title
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_f2486a20e22e430c8654899f00c91a87
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f2486a20e22e430c8654899f00c91a87
Other Identifiers
ISSN
2052-4439
E-ISSN
2052-4439
DOI
10.1136/bmjresp-2022-001563
